BenevolentAI is transforming drug development with its AI-powered knowledge graph and drug discovery platform, enabling researchers to uncover novel therapeutic targets and optimize compound selection. The platform's machine learning models integrate scientific literature, clinical data, and molecular information to generate actionable insights for pharmaceutical R&D. BenevolentAI collaborates with global pharma companies, biotech firms, and academic partners, advancing projects in neurology, immunology, and rare diseases. With robust data curation, scalable infrastructure, and a commitment to ethical AI, BenevolentAI is accelerating the path from discovery to clinical trials. SEO keywords: "BenevolentAI drug discovery," "AI knowledge graph platform," "AI pharmaceutical R&D," "intelligent compound selection," "BenevolentAI innovation."